Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?
-
By
-
Maria Jose Temido
-
Sailish Honap
-
Silvio Danese
-
Vipul Jairath
-
Fernando Magro
-
Francisco Portela
-
Laurent Peyrin-Biroulet
-
August 29, 2024
-
Objective:
To review the opportunities and challenges of nested randomized controlled trials (RCTsNC) in inflammatory bowel disease (IBD).
Key Findings:
- RCTsNC can utilize existing longitudinal data for better safety and efficacy assessments.
- They improve recruitment and follow-up processes, making trials more economical.
- Observational data from IBD registries can enhance RCTsNC performance.
- There are significant knowledge gaps in IBD that RCTsNC can help address.
Interpretation:
RCTsNC represent a promising alternative to traditional RCTs in IBD, potentially overcoming recruitment and operational challenges.
Limitations:
- Risk of selection bias.
- Challenges in making placebo comparisons.
Conclusion:
RCTsNC offer a novel approach to IBD research, addressing the limitations of conventional trial designs.
